Antiestrogenic therapy is a mainstay in the adjuvant treatment of hormone receptor–positive breast cancer and acts via different mechanisms to reduce estrogen signaling. Brain regions that are sensitive to estrogenic modulation may therefore be vulnerable to such treatments. The early effects of initiating antiestrogenic therapy on macrostructural brain measures and on mental health are not well characterized. This study reports interim longitudinal data examining whether starting tamoxifen or letrozole is associated with short-term changes in brain structure and psychological symptoms.
This is a longitudinal prospective study with two assessments: a baseline (t1) and a short-term follow-up approximately 2 to 3 weeks later (t2). Women with newly diagnosed breast cancer started antiestrogen therapy immediately after the baseline assessment. Healthy control participants underwent the same assessment schedule without any intervention. The primary aim was to detect early treatment-associated changes in structural MRI metrics and in self-reported psychological measures.
The interim sample consisted of twenty women with breast cancer (BC) and twenty healthy control women. The trial is registered as NCT06346457. Ethical approval for the study was provided by the Ethics Committee of the Medical Faculty Tuebingen (508/2023BO2, 11.10.2023), and all participants provided written informed consent.
Structural MRI analyses included whole-brain measures of cortical thickness and gyrification, as well as region-of-interest (ROI) volumetry for the hippocampus and amygdala. Total brain volume was also evaluated. Analyses tested time-by-group interactions between baseline and the 2–3 week follow-up to identify early macrostructural effects associated with initiation of antiestrogen therapy (tamoxifen or letrozole).
Participants completed psychological assessments at both time points covering depressive symptoms, state anxiety, and positive affect. Somatic depressive symptom subscales were examined specifically. The study included measurement of hormone levels; however, those hormone data are not reported in the preprint.
After correction for multiple comparisons, there were no robust time-by-group interactions for total brain volume, whole-brain cortical thickness, gyrification, or ROI volumes of the hippocampus and amygdala. In other words, at the group level in this interim sample, initiation of antiestrogenic therapy did not produce detectable macrostructural brain changes over the first 2–3 weeks post-initiation when controlling for multiple tests.
An exploratory within-patient analysis identified a localized increase in cortical thickness in the right anterior insula / inferior frontal operculum. However, this localized effect did not produce a significant time-by-group interaction after correction for multiple comparisons. The authors note this as a tentative, hypothesis-generating observation that requires replication in larger samples.
Psychological assessments revealed a significant time-by-group interaction for somatic depressive symptom scores: these scores increased in the breast cancer group between t1 and t2 but remained stable in healthy controls. Across both time points, women with breast cancer reported higher overall depressive symptoms and higher state anxiety as well as lower positive affect compared with controls.
The authors examined associations between changes in brain structural measures and psychological symptoms. Some associations reached significance at uncorrected thresholds, but none survived correction for multiple comparisons. These exploratory brain–behavior links are reported as provisional and require confirmation in larger datasets.
This report describes an interim sample and a very short follow-up interval (≈2–3 weeks). The absence of robust macrostructural changes in this dataset does not exclude the presence of subtle, spatially heterogeneous, or delayed effects of antiestrogenic therapy on brain structure. The sample size and brief follow-up reduce sensitivity to small effects and to individual variability in treatment response. Hormone level data were collected but are not presented in this preprint, limiting mechanistic interpretation. The authors emphasize that ongoing recruitment toward the prospectively defined final sample is under way to provide greater statistical power and to permit more definitive conclusions.
In this interim longitudinal MRI study, initiation of tamoxifen or letrozole in women with breast cancer was not associated with robust group-level macrostructural brain changes over the first 2–3 weeks after treatment start. However, somatic depressive symptoms increased in the breast cancer group during this early treatment period. Exploratory localized cortical thickness increases in the right anterior insula and preliminary brain–behavior associations were observed at uncorrected thresholds but did not survive multiple-comparison correction. These findings are preliminary, hypothesis-generating, and require confirmation in larger samples with longer follow-up. The study is registered (NCT06346457) and ethical approvals and informed consent were obtained.